Very strong sales in the quarter, + 53 %
– Fifth consecutive quarter of growth
1 April-30 June
- Net sales reached SEK 5,4 (3,5) million
- Loss after taxes SEK -4,1 (-3,7) million
- Earnings per share were SEK -0,07 (-0,07)
- Cash and equivalents were 34,4 (4,4) million
Significant events during period
- Distribution agreement signed in Poland
- Distribution agreement signed in Switzerland
- The Board decides on a rights issue
- The rights issue was subscribed to 85% and brought the company approximately SEK 34 million in capital before issue costs
1 January-30 June
- Net sales reached SEK 10,9 (8,1) million
- Loss after taxes SEK -7,3 (-5,8) million
- Earnings per share were SEK -0,10 (-0,11)
Significant events after the period
- The company decided to withdraw the 510(k) application in the USA, for the Schelin Catheter®
- The company decided that it intends to apply De Novo for Schelin Catheter®
| Nyckeltal | |||
| (SEK MILLION) ) | Jan-June 2023 | Jan-June 2022 | Jan-June 2021 |
| Net sales | 11 | 8,1 | 8,5 |
| Gross margin, % | 68 | 76 | 87 |
| Operating profit/loss | -7,2 | -5,8 | -3,9 |
| Cash flow from operating activities | -6,1 | -9,5 | -3,2 |
| Average number of employees | 9 | 7 | 7 |
”The great interest in all our products, not only the stand-alone products but also CoreTherm, in several countries makes us look with confidence to the future”.
Johan Wennerholm
CEO, ProstaLund AB (publ)